Chapter 156
Immunodeficiency Syndromes
Julie V. Schaffer,
Melanie Makhija,
Amy S. Paller,
Julie V. Schaffer
Division of Pediatric and Adolescent Dermatology, Hackensack University Medical Center, Hackensack, NJ, USA
Search for more papers by this authorMelanie Makhija
Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Search for more papers by this authorAmy S. Paller
Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Search for more papers by this authorJulie V. Schaffer,
Melanie Makhija,
Amy S. Paller,
Julie V. Schaffer
Division of Pediatric and Adolescent Dermatology, Hackensack University Medical Center, Hackensack, NJ, USA
Search for more papers by this authorMelanie Makhija
Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Search for more papers by this authorAmy S. Paller
Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Search for more papers by this authorBook Editor(s):Peter Hoeger,
Veronica Kinsler,
Albert Yan,
John Harper,
Arnold Oranje,
Christine Bodemer,
Margarita Larralde,
David Luk, Vibhu Mendiratta,
Diana Purvis,
Peter Hoeger
Search for more papers by this authorVeronica Kinsler
Search for more papers by this authorAlbert Yan
Search for more papers by this authorJohn Harper
Search for more papers by this authorArnold Oranje
Search for more papers by this authorChristine Bodemer
Search for more papers by this authorMargarita Larralde
Search for more papers by this authorVibhu Mendiratta
Search for more papers by this authorDiana Purvis
Search for more papers by this authorSummary
Primary immunodeficiencies represent a heterogeneous group of disorders characterized by increased susceptibility to infection and often additional features such as autoimmunity, allergy and malignancy. Mucocutaneous manifestations are often a presenting sign, allowing one to suspect the diagnosis and initiate intervention. Improved understanding of the underlying genetic and molecular basis of many of these forms of immunodeficiency has led to reversal through stem cell transplantation or, in some cases, more targeted therapy.
References
- Picard C, Gaspar HB, Al-Herz W et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee report on inborn errors of immunity. J Clin Immunol 2018; 38: 96–128.
- Azizi G, Ghanavatinejad A, Abolhassani H et al. Autoimmunity in primary T-cell immunodeficiencies. Expert Rev Clin Immunol 2016; 28: 1–18.
- Walkovich K, Connelly JA. Primary immunodeficiency in the neonate: early diagnosis and management. Semin Fetal Neonatal Med 2016; 21: 35–43.
- Chan SK, Gelfand EW. Primary immunodeficiency masquerading as allergic disease. al. Immunol Allergy Clin North Am 2015; 35: 767–78.
- Sillevis Smitt JH, Kuijpers TW. Cutaneous manifestations of primary immunodeficiency. Curr Opin Pediatr 2013; 25: 492–7.
- Relan M, Lehman HK. Common dermatologic manifestations of primary immune deficiencies. Curr Allergy Asthma Rep 2014; 14: 480.
- Mitra A, Pollock B, Gooi J et al. Cutaneous granulomas associated with primary immunodeficiency disorders. Br J Dermatol 2005; 153: 194–9.
- Torrelo A, Vera A, Portugues M et al. Perforating neutrophilic and granulomatous dermatitis of the newborn: a clue to immunodeficiency. Pediatr Dermatol 2007; 24: 211–5.
- Slatter MA, Gennery AR. An approach to the patient with recurrent infections in childhood. Clin Exp Immunol 2008; 152: 389–96.
- Mueller BU, Pizzo PA. Cancer in children with primary or secondary immunodeficiencies. J Pediatr 1995; 126: 1–10.
- Chinen J, Notarangelo LD, Shearer WT et al. Advances in basic and clinical immunology in 2014. J Allergy Clin Immunol 2015; 135: 1132–41.
- Fischer A, Hacein-Bey Abina S, Touzot F et al. Gene therapy for primary immunodeficiencies. Clin Genet 2015; 88: 507–15.
References
- Stiehm ER, Ochs HD, Winkelstein JD. Immunologic Disorders in Infants and Children, 5th edn. Philadelphia: Elsevier Saunders, 2004: 512.
- Savitsky K, Bar-Shira A, Gilad S et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995; 268: 1749–53.
- Lavin MF. Ataxia–telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008; 9: 759–69.
- Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood 2013; 121: 4036.
- Lee JH, Paull TT. ATM activation by DNA double-stranded breaks through the Mre11-Rad50-Nbs1 complex. Science 2005; 308: 551–4.
- Stracker TH, Roig I, Knobel PA et al. The ATM signaling network in development and disease. Fron Genet 2013; 4: 37.
- Cohen LE, Tanner DJ, Schaefer HG et al. Common and uncommon cutaneous findings in patients with ataxia telangiectasia. J Am Acad Dermatol 1984; 10: 431–7.
- Paller AS, Massey RB, Curtis MA et al. Cutaneous granulomatous lesions in patients with ataxia-telangiectasia. J Pediatr 1991; 119: 917–22.
- Khumalo NP, Joss DV, Huson SM, Burge S. Pigmentary anomalies in ataxia-telangiectasia: a clue to diagnosis and an example of twin spotting. Br J Dermatol 2001; 144: 369–71.
- Greenberger S, Berkun Y, Ben-Zeev B et al. Dermatologic manifestations of ataxia-telangiectasia syndrome. J Am Acad Dermatol 2013; 68: 932–6.
- Nowak-Wegrzyn A, Crawford TO, Winkelstein JA et al. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr 2004; 144: 505–11.
- Staples ER, McDermott EM, Reiman A et al. Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene. Clin Exp Immunol 2008; 153: 214–20.
- Nissenkorn A, Levy-Shraga Y, Banet-Levi Y. Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort. Pediatr Res 2016; 79: 889–94.
- Cabana MD, Crawford RO, Winkelstein JA et al. Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics 1998; 102: 98–100.
- Thompson D, Duedal S, Kirner J et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005; 97: 813–22.
- Renwick A, Thompson D, Seal S et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006; 38: 873–5.
- Crawford TO, Skolasky RL, Fernandez R et al. Survival probability in ataxia telangiectasia. Arch Dis Child 2006; 91: 610–1.
- Micol R, Ben Slama L, Suarez F et al. Morbidity and mortality from A-T are associated with ATM genotype. JACI 2011; 128: 382–389.e381
- Teresa de la Morena M. Clinical phenotypes of hyper-IgM syndromes. J Allergy Clin Immunol: In Pract 2016; 4: 1023–36.
- Kwan A, Abraham RS, Currier R, Newborn screening for severe combined immune deficiency in 11 screening programs in the United States. JAMA 2014; 312: 729–38.
- Lavin MF, Gueven N, Bottle S, Gatti RA. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br Med Bull 2007; 81–2: 129–47.
- Lai CH, Chun HH, Nahas SA et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A 2004; 10: 16982.
References
- McKusick VA, Eldridge R, Hostetler JA et al. Dwarfism in the Amish. Ii. Cartilage-Hair Hypoplasia. Bull Johns Hopkins Hosp 1965; 116: 285–326.
- Hermanns P, Bertuch AA, Bertin TK et al. Consequences of mutations in the non-coding RMRP RNA in cartilage-hair hypoplasia. Hum Mol Genet 2005; 14: 3723–40.
- Rogler LE, Kosmyna B, Moskowitz D. Small RNAs derived from IncRNA RNase MRP have gen-silencing activity relevant to human cartilage-hair hypoplasia. Hum Mol Genet 2014; 23: 368–82.
- Ridanpaa M, Van Eenennaam H, Pelin K et al. Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage–hair hypoplasia. Cell 2001; 104: 195–203.
- Brennan T, Pearson R. Abnormal elastic tissue in cartilage–hair hypoplasia. Arch Dermatol 1988; 124: 1411–14.
- Kavadas FD, Giliani S, Gu Y et al. Variability of clinical and laboratory features among patients with ribonuclease mitochondrial RNA processing endoribonuclease gene mutations. J Allergy Clin Immunol 2008; 122: 1178–84.
- Taskinen M, Ranki A, Pukkala E et al. Extended follow-up of the Finnish cartilage–hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma. Am J Med Genet A 2008; 146A: 2370–5.
- Notarangelo LD, Roifman CM, Giliani S. Cartilage–hair hypoplasia: molecular basis and heterogeneity of the immunological phenotype. Curr Opin Allergy Clin Immunol 2008; 8: 534.
- Toivianen-Salo S, Kajosaari M, Piilonen A, Mäkitie O. Patients with cartilage hair hypoplasia have an increased risk for bronchiectasis. J Pediatr 2008; 152: 422–8.
- Makitie O, Rajantie J, Kaitila I. Anemia and macrocytosis – unrecognized features in cartilage-hair hypoplasia. Acta Paediatr 1992; 81: 1026–9.
- Guggenheim R, Somech R, Grunebaum E et al. Bone marrow transplantation for cartilage-hair-hypoplasia. Bone Marrow Transplant 2006; 38: 751–6.
- Bordon V, Gennery AR, Slatter MA et al Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation. Blood 2010; 116: 27–35.
- Ip W, Gaspar HB, Kleta R et al. Variable phenotype of severe immunodeficiencies associated with RMRP gene mutations. J Clin Immunol 2015; 35: 147–57.
- Kwan A, Abraham RS, Currier R, Newborn screening for severe combined immune deficiency in 11 screening programs in the United States. JAMA 2014; 312: 729–38.
References
- Nagai K, Ochi F, Terui K et al. Clinical characteristics and outcomes of Chédiak-Higashi syndrome: a nationwide survey of Japan. Pediatr Blood Cancer 2013; 60: 1582–6.
- Introne WJ, Westbroek W, Golas GA et al. Chediak-Higashi syndrome. In: RA Pagon, MP Adam, HH Ardinger et al. (eds) GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle;1993–2016.
- Anderson LL, Paller AS, Malpass D et al. Chediak–Higashi syndrome in a black child. Pediatr Dermatol 1992; 9: 31–6.
- Barbosa MD, Nguyen QA, Tchernev VT et al. Identification of the homologous beige and Chediak–Higashi syndrome genes. Nature 1996; 382: 262–4.
- Westbroek W, Adams D, Huizing M et al. Cellular defects in Chediak–Higashi syndrome correlate with the molecular genotype and clinical phenotype. J Invest Dermatol 2007; 127: 2674–7.
- Al-Khenaizan S. Hyperpigmentation in Chediak–Higashi syndrome. J Am Acad Dermatol 2003; 49: S244–6.
- Raghuveer C, Murthy SC, Mithuna MN et al. Silvery hair with speckled dyspigmentation: Chediak-Higashi syndrome in three Indian siblings. Int J Trichology 2015; 7: 133–5.
- Kinugawa N. Epstein–Barr virus infection in Chediak–Higashi syndrome mimicking acute lymphocytic leukemia. Am J Pediatr Hematol Oncol 1990; 12: 182–6.
- Mancini AJ, Chan LS, Paller AS et al. Partial albinism with immunodeficiency. Griscelli syndrome: report of a case and review of the literature. J Am Acad Dermatol 1998; 38: 295–300.
- Menasche G, Pastural E, Feldmann J et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 2000; 25: 173–6.
- Pastural E, Barrat FJ, Dufourcq-Lagelouse R et al. Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. Nat Genet 1997; 16: 289–92.
- Ménasché G, Ho CH, Sanal O et al. Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1). J Clin Invest 2003; 112: 450–6.
- Nouriel A, Zisquit J, Helfand AM et al. Griscelli Syndrome Type 3: two new cases and review of the literature. Pediatr Dermatol 2015; 32: e245–8.
- Westbroek W, Klar A, Cullinane AR et al. Cellular and clinical report of new Griscelli syndrome type III cases. Pigment Cell Melanoma Res 2012; 25: 47–56.
- Enders A, Zieger B, Schwarz K et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky–Pudlak syndrome type II. Blood 2006; 108: 81–7.
- Gahl WA, Huizing M. Hermansky-Pudlak Syndrome. In: RA Pagon, MP Adam, HH Ardinger et al. (eds) GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle, 1993–2016.
- Wei AH, Li W. Hermansky-Pudlak syndrome: pigmentary and non-pigmentary defects and their pathogenesis. Pigment Cell Melanoma Res 2013; 26: 176–92.
- Hartley JL, Zachos NC, Dawood B et al. Mutations in TTC37 cause trichohepatoenteric syndrome (phenotypic diarrhea of infancy). Gastroenterology 2010; 138: 2388–98.
- Galve J, Martín-Santiago A, Clavero C et al. Spontaneous repigmentation of silvery hair in an infant with congenital hydrops fetalis and hypoproteinemia. Cutis 2016; 97: E1–5.
- Umeda K, Adachi S, Horikoshi Y et al. Allogeneic hematopoietic stem cell transplantation for Chediak-Higashi syndrome. Pediatr Transplant 2016; 20: 271–5.
- Hamidieh AA, Pourpak Z, Yari K et al. Hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen in pediatric patients with Griscelli syndrome type 2. Pediatr Transplant 2013; 17: 487–91.
- Trottestam H, Beutel K, Meeths M et al. Treatment of the X-linked lymphoproliferative, Griscelli and Chédiak–Higashi syndromes by HLH directed therapy. Pediatr Blood Cancer 2009; 52: 268–72.
- Lozano ML, Rivera J, Sánchez-Guiu I et al. Towards the targeted management of Chediak-Higashi syndrome. Orphanet J Rare Dis 2014; 9: 132.
References
- Segal BH, Leto TL, Gallin JI et al. Genetic, biochemical, and clinical features of the chronic granulomatous disease. Medicine 2000; 79: 170–200.
- Winkelstein JA, Marino MC, Johnston RB et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine 2000; 79: 155–69.
- Chiriaco M, Salfa I, Di Matteo G et al. Chronic granulomatous disease: clinical, molecular and therapeutic aspects. Pediatr Allergy Immunol 2016; 27: 242–53.
- Kuhns DB, Alvord WG, Heller T et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010; 363: 2600–10.
- Köker MY, Camcıoğlu Y, van Leeuwen K et al. Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients. J Allergy Clin Immunol 2013; 132: 1156–63.
- Rada BK, Geiszt M, Kaldi K et al. Dual role of phagocytic NADPH oxidase in bacterial killing. Blood 2004; 104: 2947–53.
- Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007; 5: 577–82.
- Romani L, Fallarino F, De Luca A et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 2008; 451: 211–6.
- Lekstrom-Himes JA, Kuhns DB, Alvord WG, Gallin JI. Inhibition of human neutrophil IL-8 production by hydrogen peroxide and dysregulation in chronic granulomatous disease. J Immunol 2005; 174: 411–7.
- Crotzer VL, Matute JD, Arias AA et al. Cutting edge: NADPH oxidase modulates MHC class II antigen presentation by B cells. J Immunol 2012; 189: 3800–4.
- Marciano BE, Spalding C, Fitzgerald A et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis 2015; 60: 1176–83.
- Sedel D, Huguet P, Lebbe C et al. Sweet syndrome as the presenting manifestation of chronic granulomatous disease in an infant. Pediatr Dermatol 1994; 11: 237–40.
- Prindaville B, Nopper AJ, Lawrence H, Horii KA. Chronic granulomatous disease presenting with ecthyma gangrenosum in a neonate. J Am Acad Dermatol 2014; 71: e44–5.
- Friend JC, Hilligoss DM, Marquesen M et al. Skin ulcers and disseminated abscesses are characteristic of Serratia marcescens infection in older patients with chronic granulomatous disease. J Allergy Clin Immunol 2009; 124: 164–6.
- De Ravin SS, Naumann N, Cowen EW et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol 2008; 122: 1097–103.
- Cale CM, Morton L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol 2007; 148: 79–84.
- Valentine G, Thomas TA, Nguyen T, Lai YC. Chronic granulomatous disease presenting as hemophagocytic lymphohistiocytosis: a case report. Pediatrics 2014; 134: e1727–30.
- Magnani A, Brosselin P, Beauté J et al. Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous disease. J Allergy Clin Immunol 2014; 134: 655–62.
- Jirapongsananuruk O, Malech HL, Kuhns DB et al. Diagnostic paradigm for evaluation of male patients with chronic granulomatous disease, based on the dihydrorhodamine 123 assay. J Allergy Clin Immunol 2003; 111: 374–9.
- Kang EM, Malech HL. Advances in treatment for chronic granulomatous disease. Immunol Res 2009; 43: 77–84.
- Seger RA. Modern management of chronic granulomatous disease. Br J Haematol 2008; 140: 255–66.
- Margolis DM, Melnick DA, Alling DW et al. Trimethoprim–sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990; 162: 723–6.
- Gallin JI, Alling DW, Malech HL. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003; 348: 2416–22.
- International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991; 324: 509–16.
- Noel N, Mahlaoui N, Blanche S et al. Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: a retrospective case series. J Allergy Clin Immunol 2013; 132: 997–1000.
- Migliavacca M, Assanelli A, Ferrua F et al. Pioglitazone as a novel therapeutic approach in chronic granulomatous disease. J Allergy Clin Immunol 2016; 137: 1913–5.
- Seger RA, Gungor T, Belohradsky BH et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hematopoietic allograft: a survey of the European experience, 1985–2000. Blood 2002; 100: 4344–50.
- Del Guidice I, Iori AP, Mengarelli A et al. Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literature. Ann Hematol 2003; 82: 189–92.
- Martinez CA, Shah S, Shearer WT et al. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol 2012; 129: 176–83.
- Güngör T, Teira P, Slatter M et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 2014; 383: 436–48.
- Cole T, Pearce MS, Cant AJ et al. Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol 2013; 132: 1150–5.
- Malech HL, Mapels PB, Whiting-Theoblad N et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 1997; 94: 12133–8.
- Stein S, Ott MG, Schultze-Strasser S et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16: 198–204.
- Kaufmann KB, Chiriaco M, Siler U et al. Gene therapy for chronic granulomatous disease: current status and future perspectives. Curr Gene Ther 2014: 14: 447–60.
- De Ravin SS, Reik A, Liu PQ et al. Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous disease. Nat Biotechnol 2016; 34: 424–9.
References
- Kirkpatrick CH. Chronic mucocutaneous candidiasis. Pediatr Infect Dis J 2001; 20: 197–206.
- Ahonen P, Myllärniemi S, Sipilä I et al. Clinical variation of autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322: 1829–36.
- Anonymous (Finnish–German APECED Consortium). An autoimmune disease, APECED, is caused by mutations in a novel gene featuring two PHD-type zinc-finger domains: autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy. Nat Genet 1997; 17: 399–403.
- Liston A, Lesage S, Wilson J et al. Aire regulates negative selection of organ-specific T cells. Nat Immunol 2003; 4: 350–4.
- Aschenbrenner K, D'Cruz LM, Vollmann EH et al. Selection of Foxp3(+) regulatory T cells specific for self antigen expressed and presented by Aire(+) medullary thymic epithelial cells. Nat Immunol 2007; 8: 351–8.
- Anderson MS, Su MA. AIRE expands: new roles in immune tolerance and beyond. Nat Rev Immunol 2016; 16: 247–58.
- Ferre EM, Rose SR, Rosenzweig SD et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight 2016; 1: 13.
- Ng WF, von Delwig A, Carmichael AJ et al. Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Allergy Clin Immunol 2010; 126: 1006–15.
- Soltész B, Tóth B, Sarkadi AK et al. The evolving view of IL-17-mediated immunity in defense against mucocutaneous candidiasis in humans. Int Rev Immunol 2015; 34: 348–63.
- Kisand K, Boe Wolff AS et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010; 207: 299–308.
- Wolff AS, Sarkadi AK, Maródi L et al. Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. J Clin Immunol 2013; 33: 1341–8.
- Puel A, Cypowyj S, Bustamante J et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011; 332: 65–8.
- Boisson B, Wang C, Pedergnana V et al. An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 2013; 39: 676–86.
- Ling Y, Cypowyj S, Aytekin C et al. Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J Exp Med 2015; 212: 619–31.
- Liu L1, Okada S, Kong XF et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011; 208: 1635–48.
- van de Veerdonk FL, Plantinga TS, Hoischen A et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 2011; 365: 54–61.
- Depner M, Fuchs S, Raabe J et al. The extended clinical phenotype of 26 patients with chronic mucocutaneous candidiasis due to gain-of-function mutations in STAT1. J Clin Immunol 2016; 36: 73–84.
- Toubiana J, Okada S, Hiller J, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 2016; 127: 3154–64.
- Glocker EO, Hennigs A, Nabavi M et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009; 361: 1727–35.
- Alves de Medeiros AK, Lodewick E, Bogaert DJ et al. Chronic and invasive fungal infections in a family with CARD9 deficiency. J Clin Immunol 2016; 36: 204–9.
- Ferwerda B, Ferwerda G, Plantinga TS et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361: 1760–7.
- Herrod HG. Chronic mucocutaneous candidiasis in childhood and complications of non-Candida infection: a report of the Pediatric Immunodeficiency Collaborative Study Group. J Pediatr 1990; 116: 377–82.
- Perheentupa J. Autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy. J Clin Endocrinol Metab 2006; 91: 2843–50.
- Collins SM, Dominguez M, Ilmarinen T et al. Dermatological manifestations of autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy syndrome. Br J Dermatol 2006; 156: 1088–93.
- Halabi-Tawil M, Ruemmele FM, Fraitag S et al. Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Br J Dermatol 2009; 160: 645–51.
- Caudy AA, Reddy ST, Chatila T et al. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol 2007; 119: 482–7.
- Meloni A, Furcas M, Cetani F et al. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab 2008; 93: 4389–97.
- Rautemaa R, Richardson M, Pfaller MA et al. Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED) patients. J Antimicrob Chemother 2007; 60: 889–92.
- van de Veerdonk FL, Netea MG. Treatment options for chronic mucocutaneous candidiasis. J Infect 2016; 72 Suppl: S56–60.
- Wildbaum G, Shahar E, Katz R et al. Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: complete clinical remission with restoration of IL-17 secretion. J Allergy Clin Immunol 2013; 132: 761–4.
- Higgins E, Al Shehri T, McAleer MA et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol 2015; 135: 551–3.
References
- Grumach AS, Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol 2014; 61: 110–7.
- Frank MM. Complement deficiencies. Pediatr Clin North Am 2000; 47: 1339–54.
- Truedsson L. Classical pathway deficiencies – a short analytical review. Mol Immunol 2015; 68: 14–9.
- Macedo AC, Isaac L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front Immunol 2016; 7: 55.
- Casanova JL, Abel L. Human mannose-binding lectin in immunity: friend, foe, or both? J Exp Med 2004; 199: 1295–9.
- Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine 1992; 71: 206–15.
- Zuraw BL. Hereditary angioedema. N Engl J Med 2008; 359: 1027–36.
- Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med 2001; 161: 2417–429.
- Cicardi M, Aberer W, Banerji A et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69: 602–16.
- Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356: 213–7.
- Davis AE. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100: S7–12.
- Joseph K, Tuscano TB, Kaplan AP. Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Ann Allergy Asthma Immunol 2008; 101: 279–86.
- Cinchon S, Martin L, Hennies HC et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098–104.
- Björkqvist J, de Maat S, Lewandrowski U et al. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest 2015; 125: 3132–46.
- de Maat S, Björkqvist J, Suffritti C et al. Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. J Allergy Clin Immunol 2016; 138: 1414–23.
- Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119: 267–74.
- Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1-inhibitor deficiency. Am J Gastroenterol 2006; 101: 619–27.
- Gompels MM, Lock RJ, Abinun M et al. C1-inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139: 379–94.
- Farkas H, Martinez-Saguer I, Bork K et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy 2017; 72: 300–13.
- Blanch A, Roche O, Urrutia I et al. First case of homozygous C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 118: 1330–5.
- Deroux A, Boccon-Gibod I, Fain O et al. Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema. Clin Exp Immunol 2016; 185: 332–7.
- Bork K. A decade of change: recent developments in pharmacotherapy of hereditary angioedema (HAE). Clin Rev Allergy Immunol 2016; 51: 183–92.
- Craig T, Aygören-Pürsün E, Bork K et al. WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J 2012; 5: 182–99.
- Riedl MA, Bygum A, Lumry W et al. Safety and usage of C1-inhibitor in hereditary angioedema: Berinert Registry Data. J Allergy Clin Immunol Pract 2016; 4: 963–71.
- Zuraw BL, Davis DK, Castaldo AJ, Christiansen SC.Tolerability and effectiveness of 17-α-alkylated androgen therapy for hereditary angioedema: a re-examination. J Allergy Clin Immunol Pract 2016; 4: 948–55.
- Farkas H, Varga L, Széplaki G et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007; 120: e713–22.
- Cook HT, Botto M. The complement system and the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006; 2: 330–7.
- Sontheimer RD, Racila E, Racila DM. C1q: its functions within the innate and adaptive immune responses and its role in lupus autoimmunity. J Invest Dermatol 2005; 125: 14–23.
- Cai Y, Teo BH, Yeo JG, Lu J. C1q protein binds to the apoptotic nucleolus and causes C1 protease degradation of nucleolar proteins. J Biol Chem 2015; 290: 22570–80.
- Schneider MC, Exley RM, Ram S et al. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 2007; 15: 233–40.
- Sprong T, Roos D, Weemaes C et al. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood 2006; 107: 4865–70.
- Jönsson G, Sjöholm AG, Truedsson I et al. Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 deficiency. Rheumatology 2007; 46: 1133–9.
- Ingels H, Schejbel L, Lundstedt AC et al. Immunodeficiency among children with recurrent invasive pneumococcal disease. Pediatr Infect Dis J 2015; 34: 644–51.
- Audemard-Verger A, Descloux E, Ponard D et al. Infections revealing complement deficiency in adults: a French nationwide study enrolling 41 patients. Medicine (Baltimore) 2016; 95: e3548.
- Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MA. Overview of laboratory testing and clinical presentations of complement deficiencies and dysregulation. Adv Clin Chem 2016; 77: 1–75.
- Shih AR, Murali MR. Laboratory tests for disorders of complement and complement regulatory proteins. Am J Hematol 2015; 90: 1180–6.
References
- Lischner HW, Dacou C, DiGeorge AM. Normal lymphocyte transfer (NLT) test: negative response in a patient with congenital absence of the thymus. Transplantation,1967; 5: 555–7.
- Botto LD, May K, Fernhoff et al. A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 2003; 112: 101–7.
- Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet 2007; 370: 1443–52.
- Lindsay EA, Vitelli F, Su H et al. Tbx1 haploinsufficiency in the DiGeorge syndrome region causes aortic arch defects in mice. Nature 2001; 410: 97–101.
- Lichtner P, Konig R, Hasegawa T et al. An HDR (hypoparathyroidism, deafness, renal dysplasia) syndrome locus maps distal to the DiGeorge syndrome region on 10p13/14. J Med Genet 2000: 37: 33–7.
- Daw SC, Taylor C, Kraman M et al. A common region of 10p deleted in DiGeorge and velocardiofacial syndromes. Nat Genet 1996; 13: 458–60.
- Markert ML, Hummell DS, Rosenblatt HM et al. Complete DiGeorge syndrome: persistence of profound immunodeficiency. J Pediatr 1998; 132: 15–21.
- Selim MA, Markert ML, Burchette JL et al. The cutaneous manifestations of atypical complete DiGeorge syndrome: a histopathologic and immunohistochemical study. J Cutan Pathol 2008; 35: 380–5.
- Piliero LM, Sanford AN, McDonald-McGinn DM et al., T-cell homeostasis in humans with thymic hypoplasia due to chromosome 22q11.2 deletion syndrome. Blood 2004; 103: 1020–5.
- Chinen J, Rosenblatt HM, Smith EO et al. Long-term assessment of T-cell populations in DiGeorge syndrome. J Allergy Clin Immunol 2003; 111: 573–9.
- Zemble R, Luning Prak E, McDonald K et al. Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Immunol 2010; 136: 409–18.
- Vogels A, Schevenels S, Cayenberghs R et al. Presenting symptoms in adults with the 22q11 deletion syndrome. Eur J Med Genet 2014; 57: 157.
- Bassett AS, McDonald-McGinn DM, Devriendt K et al. Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr 2011; 159: 332.
- Kwan A, Abraham RS, Currier R et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 2014; 312: 729.
- Lingman Framme J, Borte S, von Dobeln U et al. Retrospective analysis of TREC based newborn screening results and clinical phenotypes in infants with the 22q11 deletion syndrome. J Clin Immunol 2014; 34: 514.
- Knutsen AP, Baker MW, Markert ML. Interpreting low T-cell receptor excision circles in newborns with DiGeorge anomaly: Importance of assessing naive T-cell markers. J Allergy Clin Immunol 2011; 128: 1375.
References
- Grimbacher B, Holland SM, Gallin JI et al. Hyper-IgE syndrome with recurrent infections: an autosomal dominant multisystem disorder. N Engl J Med 1999; 340: 692–702.
- Farmand S, Sundin M et al Hyper-IgE syndromes: recent advances in pathogenesis, diagnostics and clinical care. Curr Opin Hematol 2015; 22: 12–22.
- Chandesris MO, Melki I, Natividad A et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine 2012; 91: e1–e19.
- Zhang Q, Davis JC, Lamborn IT et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 2009; 361: 2046–55.
- Engelhardt KR, Gertz ME, Keles S et al. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 2015; 136: 402–12.
- Aydin SE, Kilic SS, Aytekin C et al. DOCK8 deficiency: clinical and immunological phenotype and treatment options – a review of 136 patients. J Clin Immunol 2015; 35: 189–98.
- Holland SM, DeLeo FR, Elloumi HZ et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007; 357: 1608–19.
- Minegishi Y, Saito M, Tsuchiya S et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007; 448: 1058–62.
- Milner JD, Brenchley JM, Laurence A et al. Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452: 773–6.
- Minegishi Y, Saito M, Morio T et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006; 25: 745–55.
- Kreins AY, Ciancanelli MJ, Okada S et al. Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med 2015; 212: 1641–62.
- Sassi A, Lazaroski S, Wu G et al. Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels. J Allergy Clin Immunol 2014; 133: 1410–19.
- Zhang Y, Yu X, Ichikawa M et al. Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. J Allergy Clin Immunol 2014; 133: 1400–9.
- Yang L, Fliegauf M, Grimbacher B et al. Hyper-IgE syndromes: reviewing PGM3 deficiency. Curr Opin Pediatr 2014; 26: 697–703.
- Chamlin SL, McCalmont TH, Cunningham BB et al. Cutaneous manifestations of hyper-IgE syndrome in infants and children. J Pediatr 2002; 141: 572–5.
- Eberting CL, Davis J, Puck JM et al. Dermatitis and the newborn rash of hyper-IgE syndrome. Arch Dermatol 2004; 140: 1119–25.
- Chu EY, Freeman AF, Jing H et al. Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol 2012; 148: 79–84.
- Boos AC, Hagl B, Schlesinger A et al. Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern. Allergy 2014; 69: 943–53.
- Mócsai G, Gáspár K, Dajnoki Z et al. Investigation of skin barrier functions and allergic sensitization in patients with hyper-IgE syndrome. J Clin Immunol 2015; 35: 681–8.
- Sowerwine KJ, Shaw PA, Gu W et al. Bone density and fractures in autosomal dominant hyper IgE syndrome. J Clin Immunol 2014; 34: 260–4.
- Scheuerman O, Hoffer V, Cohen AH et al. Reduced bone density in patients with autosomal dominant hyper-IgE syndrome. J Clin Immunol 2013; 33: 903–8.
- Esposito L, Poletti L, Maspero C et al. Hyper-IgE syndrome: dental implications. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114: 147–53.
- Freeman AF, Collura-Burke CJ, Patronas NJ et al. Brain abnormalities in patients with hyperimmunoglobulin E syndrome. Pediatrics 2007; 119: e1121–5.
- Alsum Z, Hawwari A, Alsmadi O et al. Clinical, immunological and molecular characterization of DOCK8 and DOCK8-like deficient patients: single center experience of twenty-five patients. J Clin Immunol 2013; 33: 55–67.
- Joshi AY, Iyer VN, Boyce TG et al. Elevated serum immunoglobulin E (IgE): when to suspect hyper-IgE syndrome: a 10-year pediatric tertiary care center experience. Allergy Asthma Proc 2009; 30: 23–7.
- Hsu AP, Sowerwine KJ, Lawrence MG et al. Intermediate phenotypes in patients with autosomal dominant hyper-IgE syndrome caused by somatic mosaicism. J Allergy Clin Immunol 2013; 131: 1586–93.
- Hershkovitz T, Hassoun G, Indelman M et al. A homozygous missense mutation in PEPD encoding peptidase D causes prolidase deficiency associated with hyper-IgE syndrome. Clin Exp Dermatol 2006; 31: 435–40.
- Woellner C, Gertz EM, Schäffer AA et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol 2010; 125: 424–32.
- Pai SY, de Boer H, Massaad MJ et al. Flow cytometry diagnosis of dedicator of cytokinesis 8 (DOCK8) deficiency. J Allergy Clin Immunol 2014; 134: 221–3;e227.
- Jeppson JD, Jaffe HS, Hill HR. Use of recombinant human interferon gamma to enhance neutrophil chemotactic responses in Job syndrome of hyperimmunoglobulinemia E and recurrent infections. J Pediatr 1991; 118: 383–7.
- Al-Zahrani D, Raddadi A, Massaad M et al. Successful interferon-alpha 2b therapy for unremitting warts in a patient with DOCK8 deficiency. Clin Immunol 2014; 153: 104–8.
- Keles S, Jabara HH, Reisli I et al. Plasmacytoid dendritic cell depletion in DOCK8 deficiency: rescue of severe herpetic infections with IFN-alpha 2b therapy. J Allergy Clin Immunol 2014; 133: 1753–5.e3.
- Papan C, Hagl B, Heinz V et al. Beneficial IFN-alpha treatment of tumorous herpes simplex blepharoconjunctivitis in dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 2014; 133: 1456–8.
- Kimata H. High-dose intravenous gamma-globulin treatment for hyperimmunoglobulinemia E syndrome. J Allergy Clin Immunol 1995; 95: 771–4.
- Bard S, Paravisini A, Avilés-Izquierdo JA et al. Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab. Arch Dermatol 2008; 144: 1662–3.
- Cuellar-Rodriguez J, Freeman AF, Grossman J et al. Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency. Biol Blood Marrow Transplant 2015; 21: 1037–45.
- Gatz SA, Benninghoff U, Schutz C et al. Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation. Bone Marrow Transplant 2011; 46: 552–6.
- Boztug H, Karitnig-Weiss C, Ausserer B et al. Clinical and immunological correction of DOCK8 deficiency by allogeneic hematopoietic stem cell transplantation following a reduced toxicity conditioning regimen. Pediatr Hematol Oncol 2012; 29: 585–94.
- Patel NC, Gallagher JL, Torgerson TR et al. Successful haploidentical donor hematopoietic stem cell transplant and restoration of STAT3 function in an adolescent with autosomal dominant hyper-IgE syndrome. J Clin Immunol 2015; 35: 479–85.
References
- Conley ME. Genes required for B cell development. J Clin Invest 2003; 112: 1636–8.
- Grimbacher B, Schäffer AA, Peter HH. The genetics of hypogammaglobulinemia. Curr Allergy Asthma Rep 2004; 4: 349–58.
- Wood P, Stanworth S, Burton J et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 2007; 149: 410–23.
- Al-Attas RA, Rahi AH. Primary antibody deficiency in Arabs: first report from Eastern Saudi Arabia. J Clin Immunol 1998; 18: 368–71.
- Kanoh T, Mizumoto T, Yasuda N et al. Selective IgA deficiency in Japanese blood donors: frequency and statistical analysis. Vox Sang 1986; 50: 81–6.
- Cunningham-Rundles C. Physiology of IgA and IgA deficiency. J Clin Immunol 2001; 21: 303–9.
- Korthäuser U, Graf D, Mages HW. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993; 361: 539–40.
- DiSanto JP, Bonnefoy JY, Gauchat JF et al. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature 1993; 361: 541–3.
- Revy P, Muto T, Levy Y et al. Activation-induced cytidine deaminase (AIS) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell 2000; 102: 565–75.
- Durandy A, Peron S, Fischer A. Hyper-IgM syndromes. Curr Opin Rheumatol 2006; 18: 369–76.
- Lougaris V, Badolato R, Ferrari S, Plebani A. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol Rev 2005; 203: 48–66.
- Durandy A, Revy P, Imai K, Fischer A. Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects. Immunol Rev 2005; 203: 67–79.
- Teresa de la Morena, M Clinical phenotypes of hyper-IgM syndromes JACI in Practice 2016; 4: 1023–36.
- Winkelstein, JA, Marino MC, Ochs H et al. The X-linked hyper IGM syndrome: Clinical and immunologic features of 79 patients. Medicine (Baltimore) 2003; 82: 373–84.
- Chang MW, Romero R, Scholl PR et al. Mucocutaneous manifestations of the hyper-IgM Immunodeficiency syndrome. J Am Acad Dermatol 1998; 38: 191–6.
- Jesus AA, Duarte AJ, Oliveira JB. Autoimmunity in hyper-IgM syndrome. J Clin Immunol 2008; 28: S62–6.
- Vetrie D, Vorechovsky I, Sideras P et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1992; 361: 226–33.
- Tsukada S, Saffran DC, Rawlings DJ et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993; 72: 279–90.
- Castigli E, Wilson SA, Garibyan L et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005; 37: 829–34.
- Park MA, Li JT, Hagan JB et al. Common variable immunodeficiency: a new look at an old disease. Lancet 2008; 372: 489–502.
- Bonilla FA, Geha RS. Common variable immunodeficiency. Pediatr Res 2009; 65: 13–19R.
- Bogaert D, Dullaers M, Labrecht BN et al. Genes associated with common variable immunodeficiency: one diagnosis to rule them all? J Med Genet 2016; 53: 575–90.
- Chapel H. Common variable immunodeficiency. Diagnoses of exclusion, especially combined immune defects. J Allergy Clin Immunol: in Practice 2016; 4: 1158–9.
- Maffucci P, Filion CA, Boisson B et al. Genetic diagnosis using whole exome sequencing in common variable immunodeficiency. Front Immunol 2016; 7: 220.
- Glocker E, Ehl S, Grimbacher B. Common variable immunodeficiency in children. Curr Opin Pediatr 2007; 19: 685–92.
- Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92: 34–48.
- Ng W, Tan CL, Yeow V et al. Ecthyma gangrenosum in a patient with hypogammaglobulinemia. J Infect 1998; 36: 331–5.
- Bearden D, Collett M, Lan Quan P et al. Enteroviruses in X-linked agammaglobulimenia: update on epidemiology and therapy. J Allergy Clin Immunol: In Practice 2016; 4: 1059–65.
- Ballow M. Immunoglobulin therapy: methods of delivery. J Allergy Clin Immunol 2008; 122: 1038–9.
- Wasserman RL. The nuts and bolts of immunoglobulin treatment for antibody deficiency. J Allergy Clin Immunol: In Practice 2016; 4: 1076–1081.e3.
References
- Halabi-Tawil M, Ruemmele FM, Fraitag S et al. Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Br J Dermatol 2009; 160: 645–51.
- Caudy AA, Reddy ST, Chatila T et al. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol 2007; 119: 482–7.
References
- Malech HL, Hickstein DD. Genetics, biology and clinical management of myeloid cell primary immune deficiencies: chronic granulomatous disease and leukocyte adhesion deficiency. Curr Opin Hematol 2007; 14: 29–36.
- Bunting M, Harris ES, McIntyre TM et al. Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving β2 integrins and selectin ligands. Curr Opin Hematol 2002; 9: 30–5.
- Bauer TR, Gu YC, Creevy KE et al. Leukocyte adhesion deficiency in children and Irish Setter dogs. Pediatr Res 2004; 55: 363–7.
- Wild MK, Lühn K, Marquardt T et al. Leukocyte adhesion deficiency II: therapy and genetic defect. Cells Tissues Organs 2002; 172: 161–73.
- Kuijpers TW, van de Vijver E, Weterman MA et al. LAD-1/variant syndrome is caused by mutations in FERMT3. Blood 2009; 113: 4740–6.
- Svensson L, Howarth K, McDowall A et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med 2009; 15: 306–12.
- Helmus Y, Denecke J, Yakubenia S et al. Leukocyte adhesion deficiency II patients with a dual defect of the GDP-fucose transporter. Blood 2006; 107: 3959–66.
- Kuijpers TW, van Bruggen R, Kamerbeek N et al. Natural history and early diagnosis of LAD-1/variant syndrome. Blood 2007; 109: 3529–37.
- Kilic SS, Etzioni A. The clinical spectrum of leukocyte adhesion deficiency (LAD) III due to defective CalDAG-GEF1. J Clin Immunol 2009; 29: 117–22.
- Marquardt T, Luhn K, Srikrishna G et al. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood 1999; 94: 3976–85.
- Qasim W, Cavazzana-Calvo M, Davies EG et al. Allogeneic haematopoietic stem-cell transplantation for leukocyte adhesion deficiency. Pediatrics 2009; 123: 836–40.
- Bauer TR, Allen JM, Hai M et al. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med 2008; 14: 93–7.
References
- Fischer A, Le Deist F, Hacein-Bey-Abina S et al. Severe combined immunodeficiency: a model disease for molecular immunology and therapy. Immunol Rev 2005; 203: 98–109.
- Buckley RH. The multiple causes of human SCID. J Clin Invest 2004; 10: 1409–11.
- Gaspar HB, Gilmour KC, Jones AM. Severe combined immunodeficiency: molecular pathogenesis and diagnosis. Arch Dis Child 2001; 84: 169–73.
- Kwan A, Abraham RS, Currier R et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 2014; 312: 729–38.
- Al-Herz, W, Al-Mousa H. Combined immunodeficiency: the Middle East experience. J Allergy Clin Immunol 2013; 131: 658–60.
- Al-Herz W, Bousfiha A, Casanova JL et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2014; 5: 162.
- Postigo Llorente C, Ivars Amorós J, Ortiz de Frutos FJ et al. Cutaneous lesion in severe combined immunodeficiency: two case reports and a review of the literature. Pediatr Dermatol 1991; 8: 314–21.
- De Raeve L, Song M, Levy J et al. Cutaneous lesions as a clue to severe combined immunodeficiency. Pediatr Dermatol 1992; 9: 49–51.
- Shearer WT, Dunn E, Notarangelo LD et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID and Omenn Syndrome: the primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol 2014; 133: 1092.
- Dion, ML, Sekaly RP, Cheynier R. Estimating thymic function through quantification of T-cell receptor excision circles. Methods Mol Biol 2007; 380: 197–213.
- Papadopoulou-Alataki E, Hassan A, Davies EG. Prevention of infection in children and adolescents with primary immunodeficiency disorders. Asian Pac J Allergy Immunol 2012; 30: 239–58.
- Buckley RH, Schiff SE, Schiff RI et al. Hematopoeietic stem cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999; 340: 508–16.
- Haddad E, Landais P, Friedrich W et al. Long-term immune reconstitution and outcome after HLA-non-identical T-cell depleted bone marrow reconstitution for severe combined immunodeficiency, a European retrospective study of 116 patients. Blood 1998; 91: 3646–53.
- Thrasher AJ. Gene therapy for primary immunodeficiencies. Immunol Allergy Clin North Am 2008; 28: 457–71.
- Flake AW, Roncarolo MG, Puck JM et al. Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow. N Engl J Med 1996; 335: 1806–10.
- Naik S, Nicholas SK, Martinez CA et al. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol 2016; 137: 1498–505.
- Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669–72.
- Aiuti A, Slavin S, Aker M et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410–3.
- Gaspar HB, Parsley KL, Howe S et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gamma retroviral vector. Lancet 2004; 364: 2181–7.
- Bushman FD. Retroviral integration and human gene therapy. J Clin Invest 2007; 117: 2083–6.
- Hacein-Bey-Abina S, Garrigue A, Wang GP et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 117: 3132–42.
References
- Buchbinder D, Nugent DJ, Fillipovich AH et al. Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. App Clin Genet 2014; 7: 55–66.
- Massaad MJ, Ramesh N, Geha RS et al Wiskott-Aldrich syndrome: a comprehensive review. Ann N Y Acad Sci 2013; 1285: 26–43.
- Cotta-de-Almeida V, Dupré L, Guipouy D et al. Signal integration during T lymphocyte activation and function: lessons from the Wiskott-Aldrich syndrome. Front Immunol 2015; 6: 47.
- Dupuis-Girod S, Medioni J, Haddad E et al. Autoimmunity in Wiskott–Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 2003; 111: e622–7.
- Dosanjh A. Autoimmunity and immunodeficiency. Pediatr Rev 2015; 36: 489–94.
- Volpi S, Santori E, Abernethy K et al. N-WASP is required for B-cell-mediated autoimmunity in Wiskott-Aldrich syndrome. Blood 2016; 127: 216–20.
- Pala F, Morbach H, Castiello MC et al. Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients. J Clin Invest 2015; 125: 3941–51.
- Winkelstein JA, Fearon E et al. Carrier detection of the X-linked primary immunodeficiency diseases using X-chromosome inactivation analysis. J Allergy Clin Immunol 1990; 85: 1090–7.
- Worth AJ, Thrasher AJ. Current and emerging treatment options for Wiskott-Aldrich syndrome. Expert Rev Clin Immunol 2015; 11: 1015–32.
- Hacein-Bey Abina S, Gaspar HB, Blondeau J et al. Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. JAMA 2015; 313: 1550–63.
- Braun CJ, Boztug K, Paruzynski A et al. Gene therapy for Wiskott-Aldrich syndrome – long-term efficacy and genotoxicity. Sci Transl Med 2014; 6: 227ra33.
- Aiuti A, Biasco L, Scaramuzza S et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013; 341: 1233151.
- Laskowski TJ, Van Caeneghem Y, Pourebrahim R et al. Gene correction of iPSCs from a Wiskott-Aldrich syndrome patient normalizes the lymphoid developmental and functional defects. Stem Cell Reports 2016; 7: 139–48.
- Litzman J, Jones A, Hann I et al. Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott–Aldrich syndrome. Arch Dis Child 1996; 75: 436–9.
